Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: selvi o. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. BMC Cancer. 2023. PMID: 36765293 Free PMC article.
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y, Tatli AM, Teker F, Onder AH, Kose F, Geredeli C, Karaagac M, Kaplan MA, Inanc M, Goktas Aydin S, Kargi A, Arak H, Ozturk B, Besen AA, Selvi O, Korkmaz M, Oruc Z, Bozkurt O, Bilici A, Bayram S, Dae SA, Ozdogan M, Coskun HS, Sezgin Goksu S. Ilhan Y, et al. Among authors: selvi o. Int J Gynecol Cancer. 2022 Apr 4;32(4):502-507. doi: 10.1136/ijgc-2021-003165. Int J Gynecol Cancer. 2022. PMID: 35086927
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Dülgar Ö, et al. Among authors: selvi o. Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670. Epub 2022 Jun 1. Expert Rev Anticancer Ther. 2022. PMID: 35543015
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: selvi o. BMC Cancer. 2023 Feb 27;23(1):192. doi: 10.1186/s12885-023-10662-3. BMC Cancer. 2023. PMID: 36849943 Free PMC article. No abstract available.
The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG, Olmez OF, Selvi O, Geredeli C, Ozden F, Bilici A, Acikgoz O, Karci E, Kutlu Y, Hamdard J, Aydin A. Aydin SG, et al. Among authors: selvi o. J Gastrointest Cancer. 2023 Jun 22. doi: 10.1007/s12029-023-00953-0. Online ahead of print. J Gastrointest Cancer. 2023. PMID: 37347353
58 results